CFO
PACB icon

Callan Family Office’s Pacific Biosciences PACB Stock Holding History

Callan Family Office’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,024
Closed -$12.4K – 922
2025
Q2 		$12.4K Buy
+10,024
New +$11.6K ﹤0.01% 927

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Callan Family Office's PACB Position: Q3 2025 in Review

Callan Family Office sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 10,024 shares — an estimated $12.4K sold.

Callan Family Office first reported a position in PACB in Q2 2025 and held it in 1 quarter. The position peaked at $12.4K in Q2 2025. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • Callan Family Office reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • Callan Family Office sold 10,024 Pacific Biosciences shares in Q3 2025, an estimated $12.4K.
  • Callan Family Office first reported a position in Pacific Biosciences in Q2 2025 and held it in 1 quarter.
  • Callan Family Office's Pacific Biosciences position peaked at $12.4K in Q2 2025.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on Callan Family Office's 13F filing for Q3 2025, filed 4 Nov 2025.